AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a ...

Enhertu already has seven FDA approvals across breast cancer, gastric cancer, non-small cell lung cancer (NSCLC), and ...

Dr. Debu Tripathy breaks down the FDA approval of Enhertu in unresectable or metastatic HR-positive, HER2-low or -ultralow breast cancer. On Jan. 27, the Food and Drug Administration (FDA) granted ...

The partners are pushing to expand Enhertu’s list of indications beyond its standing uses in breast, lung and gastric cancers ...

Dr. Debu Tripathy discusses the FDA approval of Enhertu in unresectable or metastatic hormone receptor HR+, HER2-low or -ultralow breast cancer. On Jan. 27, the Food and Drug Administration (FDA) ...

The company reported a robust set of numbers for the December quarter of FY25, with its profit nearly doubling year-on-year ...

Q4 2024 Earnings Call Transcript February 27, 2025 Cardiff Oncology, Inc. beats earnings expectations. Reported EPS is $-0.22 ...

The breast cancer market has experienced robust growth, fueled by increased awareness and early detection efforts. Advances in diagnostic and treatme ...

ADCs are currently at the forefront of cancer treatment, but persistent drug development challenges call for a new approach.

Mark Erlander; Chief Executive Officer, Director; Cardiff Oncology Inc. James Levine; Chief Financial Officer; Cardi ...